Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9227194 | Journal of Allergy and Clinical Immunology | 2005 | 9 Pages |
Abstract
Humanized antibodies and decoy receptors have been introduced in clinical practice to treat malignancies and systemic autoimmune disease because they ablate specific cells or disrupt pathogenic processes at distinct points. Reported clinical responses offer hope to treatment-resistant patients, particularly those with lymphomas and rheumatic diseases. Side effects from the use of biologic agents include lymphokine release syndrome, reactivation of tuberculosis, and immunosuppression. Further insights are needed regarding limitation of adverse effects, correct use in conjunction with existing drugs, and treatment of patients in whom resistance develops.
Keywords
FDACD40LVEGFRRadioimmunotherapyCTLA4NHLLFAEGFREGFADCCRheumatoid arthritisantibody-dependent cell-mediated cytotoxicitycytotoxic T lymphocyte–associated antigen 4US Food and Drug AdministrationCrohn's diseaseCancerRITepidermal growth factorVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Lymphomanon-Hodgkin's lymphomaHodgkin's lymphomaSystemic lupus erythematosusSLECD40 ligandFusion proteinPsoriasisTransplantationvascular endothelial growth factor receptorEpidermal growth factor receptor
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Stamatis-Nick C. MD, George C. MD,